Molecular, Magnetic Resonance, and Echocardiographic Imaging Combined With Biomarkers of Cardiac and Clonal Disease to Predict Survival and Assess Response to Therapy in Cardiac AL Amyloidosis
Latest Information Update: 13 May 2025
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Amyloidosis
- Focus Diagnostic use
Most Recent Events
- 07 May 2025 Planned End Date changed from 28 Feb 2025 to 30 Jun 2025.
- 07 May 2025 Planned primary completion date changed from 28 Feb 2025 to 30 Jun 2025.
- 05 Jun 2023 Planned End Date changed from 28 Feb 2023 to 28 Feb 2025.